1032 related articles for article (PubMed ID: 24011641)
41. Physiological functions and pathobiology of TDP-43 and FUS/TLS proteins.
Ratti A; Buratti E
J Neurochem; 2016 Aug; 138 Suppl 1():95-111. PubMed ID: 27015757
[TBL] [Abstract][Full Text] [Related]
42. Genetic analysis of SIGMAR1 as a cause of familial ALS with dementia.
Belzil VV; Daoud H; Camu W; Strong MJ; Dion PA; Rouleau GA
Eur J Hum Genet; 2013 Feb; 21(2):237-9. PubMed ID: 22739338
[TBL] [Abstract][Full Text] [Related]
43. A truncating SOD1 mutation, p.Gly141X, is associated with clinical and pathologic heterogeneity, including frontotemporal lobar degeneration.
Nakamura M; Bieniek KF; Lin WL; Graff-Radford NR; Murray ME; Castanedes-Casey M; Desaro P; Baker MC; Rutherford NJ; Robertson J; Rademakers R; Dickson DW; Boylan KB
Acta Neuropathol; 2015 Jul; 130(1):145-57. PubMed ID: 25917047
[TBL] [Abstract][Full Text] [Related]
44. Lower motor neuron involvement in TAR DNA-binding protein of 43 kDa-related frontotemporal lobar degeneration and amyotrophic lateral sclerosis.
Riku Y; Watanabe H; Yoshida M; Tatsumi S; Mimuro M; Iwasaki Y; Katsuno M; Iguchi Y; Masuda M; Senda J; Ishigaki S; Udagawa T; Sobue G
JAMA Neurol; 2014 Feb; 71(2):172-9. PubMed ID: 24378564
[TBL] [Abstract][Full Text] [Related]
45. Recent advances in the genetics of the ALS-FTLD complex.
Morris HR; Waite AJ; Williams NM; Neal JW; Blake DJ
Curr Neurol Neurosci Rep; 2012 Jun; 12(3):243-50. PubMed ID: 22477152
[TBL] [Abstract][Full Text] [Related]
46. Mechanisms Associated with TDP-43 Neurotoxicity in ALS/FTLD.
Shenouda M; Zhang AB; Weichert A; Robertson J
Adv Neurobiol; 2018; 20():239-263. PubMed ID: 29916022
[TBL] [Abstract][Full Text] [Related]
47. Distinct TDP-43 inclusion morphologies in frontotemporal lobar degeneration with and without amyotrophic lateral sclerosis.
Tan RH; Yang Y; Kim WS; Dobson-Stone C; Kwok JB; Kiernan MC; Halliday GM
Acta Neuropathol Commun; 2017 Oct; 5(1):76. PubMed ID: 29078806
[TBL] [Abstract][Full Text] [Related]
48. Co-occurrence of the C9ORF72 expansion and a novel GRN mutation in a family with alternative expression of frontotemporal dementia and amyotrophic lateral sclerosis.
Testi S; Tamburin S; Zanette G; Fabrizi GM
J Alzheimers Dis; 2015; 44(1):49-56. PubMed ID: 25182743
[TBL] [Abstract][Full Text] [Related]
49. Nuclear trafficking in amyotrophic lateral sclerosis and frontotemporal lobar degeneration.
Prpar Mihevc S; Darovic S; Kovanda A; Bajc Česnik A; Župunski V; Rogelj B
Brain; 2017 Jan; 140(1):13-26. PubMed ID: 27497493
[TBL] [Abstract][Full Text] [Related]
50. Molecular and behavioural abnormalities in the FUS-tg mice mimic frontotemporal lobar degeneration: Effects of old and new anti-inflammatory therapies.
de Munter J; Babaevskaya D; Wolters EC; Pavlov D; Lysikova E; V Kalueff A; Gorlova A; Oplatchikova M; Pomytkin IA; Proshin A; Umriukhin A; Lesch KP; Strekalova T
J Cell Mol Med; 2020 Sep; 24(17):10251-10257. PubMed ID: 32667139
[TBL] [Abstract][Full Text] [Related]
51. The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease.
King OD; Gitler AD; Shorter J
Brain Res; 2012 Jun; 1462():61-80. PubMed ID: 22445064
[TBL] [Abstract][Full Text] [Related]
52. Pattern of ubiquilin pathology in ALS and FTLD indicates presence of C9ORF72 hexanucleotide expansion.
Brettschneider J; Van Deerlin VM; Robinson JL; Kwong L; Lee EB; Ali YO; Safren N; Monteiro MJ; Toledo JB; Elman L; McCluskey L; Irwin DJ; Grossman M; Molina-Porcel L; Lee VM; Trojanowski JQ
Acta Neuropathol; 2012 Jun; 123(6):825-39. PubMed ID: 22426854
[TBL] [Abstract][Full Text] [Related]
53. Molecular basis of ALS and FTD: implications for translational studies.
Liščić RM
Arh Hig Rada Toksikol; 2015 Dec; 66(4):285-90. PubMed ID: 26751860
[TBL] [Abstract][Full Text] [Related]
54. Expression of Fused in sarcoma mutations in mice recapitulates the neuropathology of FUS proteinopathies and provides insight into disease pathogenesis.
Verbeeck C; Deng Q; Dejesus-Hernandez M; Taylor G; Ceballos-Diaz C; Kocerha J; Golde T; Das P; Rademakers R; Dickson DW; Kukar T
Mol Neurodegener; 2012 Oct; 7():53. PubMed ID: 23046583
[TBL] [Abstract][Full Text] [Related]
55. Implications of the prion-related Q/N domains in TDP-43 and FUS.
Udan M; Baloh RH
Prion; 2011; 5(1):1-5. PubMed ID: 21135580
[TBL] [Abstract][Full Text] [Related]
56. Inclusions in frontotemporal lobar degeneration with TDP-43 proteinopathy (FTLD-TDP) and amyotrophic lateral sclerosis (ALS), but not FTLD with FUS proteinopathy (FTLD-FUS), have properties of amyloid.
Bigio EH; Wu JY; Deng HX; Bit-Ivan EN; Mao Q; Ganti R; Peterson M; Siddique N; Geula C; Siddique T; Mesulam M
Acta Neuropathol; 2013 Mar; 125(3):463-5. PubMed ID: 23378033
[No Abstract] [Full Text] [Related]
57. TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration.
Lagier-Tourenne C; Polymenidou M; Cleveland DW
Hum Mol Genet; 2010 Apr; 19(R1):R46-64. PubMed ID: 20400460
[TBL] [Abstract][Full Text] [Related]
58. Clinical implications of recent breakthroughs in amyotrophic lateral sclerosis.
Van Damme P; Robberecht W
Curr Opin Neurol; 2013 Oct; 26(5):466-72. PubMed ID: 23945281
[TBL] [Abstract][Full Text] [Related]
59. TARDBP and FUS mutations associated with amyotrophic lateral sclerosis: summary and update.
Lattante S; Rouleau GA; Kabashi E
Hum Mutat; 2013 Jun; 34(6):812-26. PubMed ID: 23559573
[TBL] [Abstract][Full Text] [Related]
60. Screening UBQLN-2 in French frontotemporal lobar degeneration and frontotemporal lobar degeneration-amyotrophic lateral sclerosis patients.
Lattante S; Le Ber I; Camuzat A; Pariente J; Brice A; Kabashi E;
Neurobiol Aging; 2013 Aug; 34(8):2078.e5-6. PubMed ID: 23582661
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
